CN116249711A - SARS－CoV－2中和抗体或其片段 - Google Patents

SARS－CoV－2中和抗体或其片段 Download PDF

Info

Publication number
CN116249711A
CN116249711A CN202180064994.1A CN202180064994A CN116249711A CN 116249711 A CN116249711 A CN 116249711A CN 202180064994 A CN202180064994 A CN 202180064994A CN 116249711 A CN116249711 A CN 116249711A
Authority
CN
China
Prior art keywords
amino acid
chain variable
seq
variable region
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180064994.1A
Other languages
English (en)
Chinese (zh)
Inventor
竹下胜
竹内勤
铃木胜也
佐谷秀行
高桥宜圣
森山彩野
福山英启
冈村千绘子
白水美香子
松本武久
镰田胜彦
伊藤靖
石垣宏仁
仲山美沙子
北川善纪
河冈义裕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keio School
National Institute of Infectious Diseases
Shiga University of Medical Science NUC
University of Tokyo NUC
RIKEN
Original Assignee
Keio School
National Institute of Infectious Diseases
Shiga University of Medical Science NUC
University of Tokyo NUC
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio School, National Institute of Infectious Diseases, Shiga University of Medical Science NUC, University of Tokyo NUC, RIKEN filed Critical Keio School
Publication of CN116249711A publication Critical patent/CN116249711A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
CN202180064994.1A 2020-09-25 2021-09-24 SARS－CoV－2中和抗体或其片段 Pending CN116249711A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020161205 2020-09-25
JP2020-161205 2020-09-25
JP2021-012394 2021-01-28
JP2021012394 2021-01-28
PCT/JP2021/035159 WO2022065445A1 (ja) 2020-09-25 2021-09-24 ＳＡＲＳ－ＣｏＶ－２中和抗体又はその断片

Publications (1)

Publication Number Publication Date
CN116249711A true CN116249711A (zh) 2023-06-09

Family

ID=80846662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180064994.1A Pending CN116249711A (zh) 2020-09-25 2021-09-24 SARS－CoV－2中和抗体或其片段

Country Status (6)

Country Link
US (1) US20230348573A1 (https=)
EP (1) EP4219548A1 (https=)
JP (1) JPWO2022065445A1 (https=)
KR (1) KR20230042598A (https=)
CN (1) CN116249711A (https=)
WO (1) WO2022065445A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024019110A1 (ja) * 2022-07-20 2024-01-25 国立感染症研究所長が代表する日本国 ＳＡＲＳ－ＣｏＶ－２に対する抗体
WO2024053719A1 (ja) * 2022-09-08 2024-03-14 国立大学法人熊本大学 コロナウイルス変異株に対するヒト抗体またはその抗原結合断片
WO2024151583A2 (en) * 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111423508A (zh) * 2020-03-31 2020-07-17 江苏省疾病预防控制中心(江苏省公共卫生研究院) 一种分离的抗病毒感染的SARS-CoV-2蛋白结合分子
CN111560070A (zh) * 2020-05-27 2020-08-21 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒np蛋白的抗体及其检测应用
CN111620946A (zh) * 2020-05-09 2020-09-04 江苏省疾病预防控制中心(江苏省公共卫生研究院) 分离的新型冠状病毒单克隆抗体或其抗原结合部分
CN111647077A (zh) * 2020-06-02 2020-09-11 深圳市因诺赛生物科技有限公司 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7481994B2 (ja) 2018-12-17 2024-05-13 カシオ計算機株式会社 信号検出装置、信号検出方法及び信号検出プログラム
JP7159094B2 (ja) 2019-03-27 2022-10-24 日本発條株式会社 ディスク装置のカバー構造
CN111592595B (zh) * 2020-04-27 2021-02-19 南京医科大学 抗新型冠状病毒SARS-Cov-2的中和性抗体及其应用
CN111690059B (zh) * 2020-06-19 2022-03-08 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的单克隆抗体1D7

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111423508A (zh) * 2020-03-31 2020-07-17 江苏省疾病预防控制中心(江苏省公共卫生研究院) 一种分离的抗病毒感染的SARS-CoV-2蛋白结合分子
CN111620946A (zh) * 2020-05-09 2020-09-04 江苏省疾病预防控制中心(江苏省公共卫生研究院) 分离的新型冠状病毒单克隆抗体或其抗原结合部分
CN111560070A (zh) * 2020-05-27 2020-08-21 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒np蛋白的抗体及其检测应用
CN111647077A (zh) * 2020-06-02 2020-09-11 深圳市因诺赛生物科技有限公司 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用

Also Published As

Publication number Publication date
US20230348573A1 (en) 2023-11-02
EP4219548A1 (en) 2023-08-02
JPWO2022065445A1 (https=) 2022-03-31
KR20230042598A (ko) 2023-03-28
WO2022065445A1 (ja) 2022-03-31

Similar Documents

Publication Publication Date Title
CN108640989B (zh) 可结合并中和b型流感病毒的人类结合分子及其用途
CN113354732B (zh) 针对埃博拉病毒糖蛋白的人抗体
KR101418606B1 (ko) Ｈｅｒ-３ 지향 항체 및 그 용도
CN108064240B (zh) 针对流感血凝素的人抗体
KR101516569B1 (ko) 사람 델타 유사 리간드 4에 대한 사람 항체
ES2694153T3 (es) Anticuerpos anti-ErbB3 y usos de los mismos
KR20210113936A (ko) 항-코로나바이러스 항체 및 사용 방법
CN115768790A (zh) 针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的人单克隆抗体
CN115315443A (zh) 抗sars-cov-2抗体和其用途
TW202235432A (zh) 中和抗ｓａｒｓ－ｃｏｖ－２抗體
CN114685652B (zh) 针对SARS-CoV-2和SARS-CoV的全人广谱交叉中和抗体及其应用
KR20220038415A (ko) 엔테로바이러스 d68에 대한 인간 모노클로날 항체
CA2508375A1 (en) Antibodies directed to tumor necrosis factor and uses thereof
AU2017237543A1 (en) Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same
CN102046654A (zh) 针对甲型流感病毒h5n1株系的抗体
KR20140012098A (ko) 인플루엔자의 치료 및 진단을 위한 조성물 및 방법
KR20240006575A (ko) SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도
KR20230142790A (ko) 코로나바이러스 스파이크 단백질(spike protein)을 타겟팅하는 항체
CN116249711A (zh) SARS－CoV－2中和抗体或其片段
CN114805558A (zh) 强力地中和狂犬病毒和其它狂犬病毒属病毒的抗体和其用途
KR20190077306A (ko) 항-o2 항체 및 이의 용도
CN114685653B (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
KR20210046725A (ko) 신규 암 면역요법 항체 조성물
KR102467943B1 (ko) 항-rsv 항체 및 이를 포함하는 약학적 조성물
KR20230083288A (ko) 코로나바이러스 스파이크 단백질에 대한 단일클론 항체, 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination